🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to researchers.

An International Health Concern

Cases of gonorrhoea are escalating globally, with figures suggesting more than 82 million infections per year. Especially elevated rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization represents a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which combines two antibiotics. The study included over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in numerous developing nations.

Clinicians on the front lines have shared hope. Access to a one-pill regimen of this kind is hailed as a "critical tool" for public health efforts. This is viewed as essential to lessen the impact of the disease for patients and to halt the transmission of extremely resistant gonorrhoea around the world.